| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer [Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and FLLTRILTI peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTI peptide |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
258 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). |
| Synonyms |
Hepatitis B virus; MHC; HBV |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
